FI3511319T3 - Lysiinispesifisen demetylaasi-1:n inhibiittoreita - Google Patents
Lysiinispesifisen demetylaasi-1:n inhibiittoreita Download PDFInfo
- Publication number
- FI3511319T3 FI3511319T3 FIEP19156976.3T FI19156976T FI3511319T3 FI 3511319 T3 FI3511319 T3 FI 3511319T3 FI 19156976 T FI19156976 T FI 19156976T FI 3511319 T3 FI3511319 T3 FI 3511319T3
- Authority
- FI
- Finland
- Prior art keywords
- yyli
- tiatsol
- aminopiperidin
- metyyli
- oksopyrimidin
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
- 239000004472 Lysine Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polyamides (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020886P | 2014-07-03 | 2014-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3511319T3 true FI3511319T3 (fi) | 2023-07-20 |
Family
ID=55019883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19156976.3T FI3511319T3 (fi) | 2014-07-03 | 2015-06-29 | Lysiinispesifisen demetylaasi-1:n inhibiittoreita |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US9902719B2 (enExample) |
| EP (2) | EP3511319B1 (enExample) |
| JP (2) | JP6663866B2 (enExample) |
| KR (1) | KR102475498B1 (enExample) |
| CN (2) | CN106795103B (enExample) |
| AU (1) | AU2015284383B2 (enExample) |
| BR (1) | BR112017000043A2 (enExample) |
| CA (1) | CA2954049A1 (enExample) |
| CL (1) | CL2016003422A1 (enExample) |
| CO (1) | CO2017000549A2 (enExample) |
| CY (1) | CY1125127T1 (enExample) |
| DK (2) | DK3511319T3 (enExample) |
| EA (2) | EA201891526A3 (enExample) |
| EC (1) | ECSP17006821A (enExample) |
| ES (2) | ES2948782T3 (enExample) |
| FI (1) | FI3511319T3 (enExample) |
| HR (2) | HRP20220414T1 (enExample) |
| HU (2) | HUE062558T2 (enExample) |
| IL (2) | IL249881B (enExample) |
| LT (2) | LT3511319T (enExample) |
| MX (2) | MX395534B (enExample) |
| PL (2) | PL3511319T3 (enExample) |
| PT (2) | PT3164380T (enExample) |
| RS (2) | RS64423B1 (enExample) |
| SA (1) | SA517380651B1 (enExample) |
| SG (2) | SG11201610975RA (enExample) |
| SI (2) | SI3511319T1 (enExample) |
| SM (2) | SMT202200136T1 (enExample) |
| WO (1) | WO2016003917A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016198649A1 (en) | 2015-06-12 | 2016-12-15 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| AU2017233898B2 (en) | 2016-03-15 | 2022-12-15 | Oryzon Genomics, S.A. | Combinations of LSD1 inhibitors for use in the treatment of solid tumors |
| ES3042059T3 (en) | 2016-03-16 | 2025-11-18 | Oryzon Genomics Sa | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| MY204406A (en) | 2017-08-03 | 2024-08-27 | Oryzon Genomics Sa | Methods of treating behavior alterations |
| EP3833670B1 (en) * | 2018-08-10 | 2024-04-17 | Navire Pharma, Inc. | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
| EP3907225A4 (en) * | 2019-02-01 | 2022-09-14 | Hanmi Pharm. Co., Ltd. | COMPOUNDS DERIVED FROM IMIDAZOPYRIDINE AND THEIR USE |
| US12479845B2 (en) | 2019-02-01 | 2025-11-25 | Hanmi Pharm. Co., Ltd. | Imidazopyridine derivative compounds and use of same |
| BR112021016064A2 (pt) | 2019-03-20 | 2021-10-05 | Oryzon Genomics, S.A. | Métodos de tratamento do transtorno de personalidade borderline |
| CN120837494A (zh) | 2019-03-20 | 2025-10-28 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| US11360505B2 (en) | 2020-02-11 | 2022-06-14 | Simmonds Precision Products, Inc. | Distributed network time synchronization |
| CN114105950B (zh) * | 2020-08-31 | 2022-09-06 | 南京明德新药研发有限公司 | 吡唑类化合物及其应用 |
| WO2022188709A1 (zh) * | 2021-03-11 | 2022-09-15 | 南京明德新药研发有限公司 | 噻吩类化合物及其应用 |
| WO2022199662A1 (zh) * | 2021-03-24 | 2022-09-29 | 四川汇宇制药股份有限公司 | 一种多环化合物及其应用 |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| CN116102533A (zh) * | 2021-11-11 | 2023-05-12 | 中国科学院上海药物研究所 | 一种芳杂环类化合物及其应用 |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| AU2023385514A1 (en) | 2022-11-24 | 2025-07-10 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1963188A1 (de) * | 1969-12-17 | 1971-06-24 | Bayer Ag | Neue Cyanphenyl-1,4-dihydropyridinderivate |
| AU2002214546A1 (en) * | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Bicyclic pyrimidin-4-one based inhibitors of factor xa |
| US7365069B2 (en) * | 2002-04-10 | 2008-04-29 | Bexel Pharmaceuticals Inc. | Pyrimidone derivatives |
| JP2005170792A (ja) * | 2002-11-22 | 2005-06-30 | Mitsubishi Pharma Corp | Ｌ−プロリン誘導体およびその医薬としての用途。 |
| EP1695969A4 (en) * | 2003-12-11 | 2008-11-26 | Mitsubishi Tanabe Pharma Corp | ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE |
| WO2006073167A1 (ja) * | 2005-01-07 | 2006-07-13 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
| PL372332A1 (pl) * | 2005-01-19 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| WO2006129181A2 (en) * | 2005-06-03 | 2006-12-07 | Orchid Research Laboratories Limited | Preparation of 4-pyrimidone derivatives for treating inflammatory diseases |
| ES2397400T3 (es) * | 2005-09-01 | 2013-03-06 | Eli Lilly & Company | 6-arilalquilamino-2,3,4,5-tetrahidro-1H-benzo[D]azepinas como agonistas del receptor 5-HT2C |
| JP2007197324A (ja) * | 2006-01-23 | 2007-08-09 | Toray Ind Inc | ２，４，５−置換−１，３−アゾール誘導体 |
| US7652018B2 (en) | 2006-08-15 | 2010-01-26 | Wyeth Llc | Imidazolidin-2-one derivatives useful as PR modulators |
| TW200815428A (en) * | 2006-08-15 | 2008-04-01 | Wyeth Corp | Oxazolidone derivatives as PR modulators |
| PE20081803A1 (es) | 2007-03-09 | 2008-12-11 | Wyeth Corp | Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo |
| CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| WO2009132310A1 (en) * | 2008-04-25 | 2009-10-29 | Wisconsin Alumni Research Foundation | Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth |
| WO2011130515A1 (en) | 2010-04-14 | 2011-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| WO2013132380A1 (en) * | 2012-03-06 | 2013-09-12 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| WO2015089192A1 (en) * | 2013-12-11 | 2015-06-18 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| JP2017505787A (ja) * | 2014-02-14 | 2017-02-23 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法 |
| SG11201609033TA (en) * | 2014-05-01 | 2016-11-29 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
| FR3020945B1 (fr) | 2014-05-16 | 2016-05-06 | Oreal | Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier |
| ES2812626T3 (es) * | 2014-06-27 | 2021-03-17 | Celgene Quanticel Res Inc | Inhibidores de la desmetilasa 1 específica de lisina |
| ES2905280T3 (es) * | 2014-07-03 | 2022-04-07 | Celgene Quanticel Res Inc | Inhibidores de la desmetilasa 1 específica de lisina |
-
2015
- 2015-06-29 SG SG11201610975RA patent/SG11201610975RA/en unknown
- 2015-06-29 MX MX2020010900A patent/MX395534B/es unknown
- 2015-06-29 SI SI201531948T patent/SI3511319T1/sl unknown
- 2015-06-29 EP EP19156976.3A patent/EP3511319B1/en active Active
- 2015-06-29 WO PCT/US2015/038345 patent/WO2016003917A1/en not_active Ceased
- 2015-06-29 SG SG10201802501RA patent/SG10201802501RA/en unknown
- 2015-06-29 HR HRP20220414TT patent/HRP20220414T1/hr unknown
- 2015-06-29 ES ES19156976T patent/ES2948782T3/es active Active
- 2015-06-29 PT PT158140384T patent/PT3164380T/pt unknown
- 2015-06-29 AU AU2015284383A patent/AU2015284383B2/en not_active Ceased
- 2015-06-29 FI FIEP19156976.3T patent/FI3511319T3/fi active
- 2015-06-29 MX MX2017000168A patent/MX376207B/es active IP Right Grant
- 2015-06-29 SM SM20220136T patent/SMT202200136T1/it unknown
- 2015-06-29 CN CN201580047448.1A patent/CN106795103B/zh not_active Expired - Fee Related
- 2015-06-29 DK DK19156976.3T patent/DK3511319T3/da active
- 2015-06-29 KR KR1020177003162A patent/KR102475498B1/ko active Active
- 2015-06-29 US US15/323,277 patent/US9902719B2/en active Active
- 2015-06-29 HU HUE19156976A patent/HUE062558T2/hu unknown
- 2015-06-29 HU HUE15814038A patent/HUE058852T2/hu unknown
- 2015-06-29 CN CN201810425583.0A patent/CN108530424B/zh not_active Expired - Fee Related
- 2015-06-29 HR HRP20230595TT patent/HRP20230595T1/hr unknown
- 2015-06-29 JP JP2016575768A patent/JP6663866B2/ja not_active Expired - Fee Related
- 2015-06-29 EP EP15814038.4A patent/EP3164380B1/en active Active
- 2015-06-29 ES ES15814038T patent/ES2907676T3/es active Active
- 2015-06-29 EA EA201891526A patent/EA201891526A3/ru unknown
- 2015-06-29 EA EA201790085A patent/EA033698B1/ru not_active IP Right Cessation
- 2015-06-29 PT PT191569763T patent/PT3511319T/pt unknown
- 2015-06-29 PL PL19156976.3T patent/PL3511319T3/pl unknown
- 2015-06-29 CA CA2954049A patent/CA2954049A1/en not_active Abandoned
- 2015-06-29 RS RS20230452A patent/RS64423B1/sr unknown
- 2015-06-29 DK DK15814038.4T patent/DK3164380T3/da active
- 2015-06-29 RS RS20220311A patent/RS63074B1/sr unknown
- 2015-06-29 LT LTEP19156976.3T patent/LT3511319T/lt unknown
- 2015-06-29 SI SI201531797T patent/SI3164380T1/sl unknown
- 2015-06-29 LT LTEPPCT/US2015/038345T patent/LT3164380T/lt unknown
- 2015-06-29 PL PL15814038T patent/PL3164380T3/pl unknown
- 2015-06-29 SM SM20230205T patent/SMT202300205T1/it unknown
- 2015-06-29 BR BR112017000043-1A patent/BR112017000043A2/pt not_active Application Discontinuation
-
2016
- 2016-12-30 CL CL2016003422A patent/CL2016003422A1/es unknown
-
2017
- 2017-01-01 IL IL249881A patent/IL249881B/en active IP Right Grant
- 2017-01-02 SA SA517380651A patent/SA517380651B1/ar unknown
- 2017-01-23 CO CONC2017/0000549A patent/CO2017000549A2/es unknown
- 2017-02-01 EC ECIEPI20176821A patent/ECSP17006821A/es unknown
-
2018
- 2018-01-10 US US15/867,397 patent/US10100046B2/en active Active
- 2018-09-05 US US16/122,703 patent/US20190002456A1/en not_active Abandoned
-
2019
- 2019-02-21 JP JP2019029856A patent/JP6768857B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-19 IL IL272130A patent/IL272130B/en active IP Right Grant
-
2022
- 2022-04-11 CY CY20221100269T patent/CY1125127T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3511319T3 (fi) | Lysiinispesifisen demetylaasi-1:n inhibiittoreita | |
| FI3746437T3 (fi) | Proteiinikinaasi mkk4:n estäjiä maksan regeneraation edistämiseen tai maksasolujen kuolemisen vähentämiseen tai ehkäisyyn | |
| JO3062B1 (ar) | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري | |
| AR102852A1 (es) | Inhibidores heterocíclicos de la calicreína plasmática | |
| EA202091120A2 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| SMT202000481T1 (it) | Derivati di 5-[2-(piridin-2-ilammino)-1,3-tiazol-5-il]-2,3-diiidro-1h-isoindol-1-one e loro uso come doppi inibitori di fosfatidilinositolo 3-chinasi delta e gamma | |
| IL267557B (en) | Process for the preparation of 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl[ethoxy]phenyl]methyl]-2,4-thiazolidinedione and their salts | |
| NZ629636A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions | |
| IL279186A (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts | |
| DK3057967T3 (da) | Ny krystallin form for 2-{3-[2-(1-{[3,5-bis(difluormethyl)-1h-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorphenylmethansulfonat | |
| HUE054346T2 (hu) | 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére | |
| CL2017001478A1 (es) | Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr) | |
| NZ716494A (en) | Processes and intermediates for the preparation of a pde10 inhibitor | |
| SI3019497T1 (sl) | Nova sol 3-((3-((4-(4-morfolinilmetil)-1h-pirol-2-il)metilen)-2-okso- 2,3-dihidro-1h-indol-5-il)metil)-1,3-tiazolidin-2,4-diona, njen sestavek in formulacije, ki jo vsebujejo | |
| HRP20180760T1 (hr) | Kombinacija između 3-[(3-{[4-(4-morfolinilmetil)-1h-pirol-2-il]metilen}-2-okso-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona i egfr tir-kinaze inhibitora | |
| HK40115548A (zh) | 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 | |
| HK40049678A (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts | |
| HK40025190A (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| TN2013000142A1 (en) | Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor |